Conference

38th European Congress of Pathology

European Society of Pathology

Book a meeting with us

September 12-15

Stokholm, Sweden

Booth #126

Discover COMET™ and RNAscope™ — spatial biology built for clinical pathology workflows

Meet the Bio-Techne Spatial team at ECP 2026 in Stockholm and see how RNAscope™ and COMET™ bring fullyautomated, same-section spatial multiomics into standard pathology workflows, using your own validated antibodies and without the need for antibody conjugation or barcoding.

 

Why stop by booth #126 

ECP brings together the pathologists, molecular biologists, and diagnostics teams who are the core users of COMET™ and RNAscope™. If you stop by our booth, here’s what we’ll walk you through. 

 

Your IHC antibodies and RNAscope™ probes, multiplexed 

Bring your existing IHC/IF and ISH know-how straight on to COMET™. Use off-the-shelf, unconjugated primary antibodies without the need to barcode or validate upstream conjugations. 

 

Slide in, image out 

A fully automated run takes a slide from RNAscope™ and seqIF™ staining through image acquisition and pre-processing, with tissue morphology and epitope stability preserved for use in downstream applications. 

 

Data that fits your analysis pipeline 

Start your high-plex image analysis journey with HORIZON™ Image Analysis Software, built by Bio-Techne Spatial for COMET™-generated seqIF™ and RNAscope™ data. Do you prefer your own pipeline? COMET™ and RNAscope™ data are also proven compatible with HALO®, Oncotopix® Discovery, QuPath, and Nucleai.

 

Know before you go  

You can download and read the same materials our team will be handing out at the booth or pick them up in Stockholm from booth #126

  1. The clinical utility of COMET sequential immunofluorescence in lymphoma tissue diagnostics: next generation diagnosis.
  2. A novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution identified predictive spatial biomarkers in immunotherapy- and targeted therapy-treated melanoma patients
  3. Translating clinically validated antibodies into a multiplexed immunofluorescent panel for the spatial profiling of lymphoid malignancies